Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 0 | 688 | 198 | 168 | 174 |
| Gross Profit | N/A | 688 | 198 | 168 | 174 |
| Operating Expenses | 18,337 | 159,934 | 19,004 | 19,330 | 18,929 |
| Operating Income | -18,337 | -159,246 | -18,806 | -19,162 | -18,755 |
| Other Income | -21,767 | -57,828 | 348 | 404 | 312 |
| Pre-tax Income | -40,104 | -217,074 | -18,458 | -18,758 | -18,443 |
| Income Tax | 3 | -7 | -36 | 64 | -209 |
| Net Income Continuous | -40,107 | -217,067 | -18,422 | -18,822 | -18,234 |
| Net Income | $-40,107 | $-217,081 | $-18,422 | $-18,822 | $-18,234 |
| EPS Basic Total Ops | -0.86 | -40.14 | -4.89 | -4.02 | -4.84 |
| EPS Basic Continuous Ops | -9.34 | -56.79 | -4.89 | -3.98 | -4.84 |
| EPS Diluted Total Ops | -0.86 | -40.14 | -4.89 | -4.02 | -4.84 |
| EPS Diluted Continuous Ops | -9.34 | -56.79 | -4.89 | -3.98 | -4.84 |
| EBITDA(a) | $-18,337 | $-158,830 | $-18,258 | $-18,824 | $-18,405 |